Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Q3 2022 vs. Q2 2022
How the institutions holding Navidea Biopharmaceuticals, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 26 | 25 | −1 |
| Shares | 1.50M | 1.51M | +5.19K (+0.3%) |
| Value | $1.08M | $379.6K | −$698.7K (−64.8%) |
New holders (3)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 40,146 | $10.0K | 0.00% |
| Virtu Financial LLC | 38,211 | $10.0K | 0.00% |
| Hudson Bay Capital Management LP | 11,110 | $3.00K | 0.00% |
Sold out (4)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Citadel Advisors LLC | 24,217 | $17.0K |
| Two Sigma Securities, LLC | 13,510 | $10.0K |
| Captrust Financial Advisors | 4 | $0 |
| CoreCap Advisors, LLC | 45 | $0 |